Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Adverse Events / Safety & Nivolumab

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma
Suo et al. 2020
Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab
Jotatsu et al. 2018
Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis
Xing et al. 2019
Review
Linear IgA Disease of the Gingiva Following Nivolumab Therapy
Jonna et al. 2019 Journal of Immunotherapy. 42(9): 345-347
Radiologic features of pneumonitis associated with nivolumab in NSCLC & malignant melanoma
Baba et al. 2019
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Pts With Advanced Melanoma
Weber et al. 2017a J Clin Oncol. 35: 785-92
The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
Wu et al. 2025 Front Immunol 16: 1605958

7/1/2026